Quick Facts: Modasomil Therapeutic Overview

• Condition Focus: Excessive daytime sleepiness
• Primary Uses: Narcolepsy, Obstructive Sleep Apnea (OSA), and Shift Work Disorder (SWD)
• Goal: To promote wakefulness in adult patients

---

Modasomil is a prescription medication used to address excessive sleepiness experienced by adult patients with specific diagnosed sleep disorders. The medication may help improve wakefulness and alertness during the day or during scheduled working hours.

Modasomil is indicated for the management of symptoms associated with three primary conditions:

1. Narcolepsy: It is used to reduce the persistent feeling of daytime sleepiness in individuals with this chronic condition.
2. Obstructive Sleep Apnea (OSA): Modasomil serves as an adjunct to standard therapies, such as Continuous Positive Airway Pressure (CPAP), to manage residual excessive sleepiness.
3. Shift Work Disorder (SWD): This medication can be utilized to improve wakefulness in those who have excessive sleepiness related to working night shifts or rotating shifts.

It is important for patients with Obstructive Sleep Apnea to understand that Modasomil is intended to treat the symptom of excessive sleepiness, but does not substitute for the primary treatment of the underlying airway obstruction.

Regulatory References

1. FDA drug labeling guidance

Who can and cannot use Modasomil?

The official eligibility profile for Modasomil (Modafinil) is defined by strict regulatory criteria from governmental sources (FDA, EMA) and is primarily restricted to adult patients (17 or 18 years and older) for diagnosed sleep disorders. The use is strictly prohibited or restricted for several specific populations.

---

Absolute Contraindications

Modasomil must not be used by individuals with a known history of hypersensitivity to modafinil or armodafinil. It is also contraindicated for patients diagnosed with uncontrolled moderate to severe hypertension or known cardiac arrhythmias.

---

Population Restrictions

Population Group	Regulatory Status
Pediatric Patients	Not approved; safety and effectiveness are not established.
Pregnant Females	Contraindicated; females of reproductive potential must use effective non-hormonal contraception.
Severe Hepatic Impairment	Requires a mandatory dosage reduction to one-half the usual amount.
Geriatric Patients	Use requires close monitoring and consideration for lower doses.

---

Eligibility is conditional on organ function and health history. Patients with severe renal impairment require caution, and use is not recommended for individuals with a history of Left Ventricular Hypertrophy or specific psychiatric conditions like psychosis or mania.

Interactions with other medicines and products

Modasomil (modafinil) can interact with numerous other medicines primarily by affecting the liver enzymes responsible for drug metabolism, known as the cytochrome P450 (CYP) system.

Interacting Product Category	Effect on the Interacting Product
Hormonal Contraceptives (e.g., Ethinyl Estradiol)	Effectiveness may be reduced due to CYP3A4 enzyme induction by Modasomil, leading to a risk of unintended pregnancy. Alternative or concomitant non-hormonal contraception is necessary during treatment and for two months after stopping Modasomil.
Warfarin (an anticoagulant)	Potential for decreased clearance (via CYP2C9), which may increase the risk of bleeding. Close and frequent monitoring of Prothrombin Time (INR) is required, especially during the first two months of therapy and following dosage changes.
CYP3A4 Substrates (e.g., Triazolam, Midazolam, Ciclosporin)	Systemic exposure may be decreased due to CYP3A4 enzyme induction, potentially reducing the efficacy of the co-administered drug.
CYP2C19 Substrates (e.g., Diazepam, Phenytoin, Omeprazole)	Plasma concentrations may be increased due to Modasomil's reversible inhibition of the CYP2C19 enzyme, which may increase the risk of side effects. Dosage adjustments for the co-administered drug may be necessary.

Co-administration with potent CYP enzyme inducers like Carbamazepine and Phenobarbital may reduce Modasomil's plasma levels. Patients should be monitored for signs of toxicity or loss of efficacy of any co-administered medicine.

How Modasomil Works: The Mechanism of Action

Modulation of the Dopamine Transporter

The drug's primary action begins at the Dopamine Transporter (DAT), which mediates the reuptake of dopamine from the synaptic cleft. Modasomil functions as a weak reuptake inhibitor, leading to an increase in the extracellular concentration of dopamine in specific brain circuits. This increase in dopaminergic signaling is associated with the modulation of reward and arousal circuits. The mechanism involves reuptake blockade, which contrasts with agents that promote the direct release of monoamines.

Enhancement of Wakefulness Pathways

The elevated dopamine signaling initiates a cascade that modulates the activity of key endogenous arousal systems: the Orexin (Hypocretin) and Histamine pathways, located in the hypothalamus. Modasomil indirectly activates these neurons, which project widely throughout the brain. The mechanism's influence on neuropeptide signaling reflects its eugeroic profile and contributes to the stabilization of wakefulness-related signaling.

Adjusting CNS Signaling Balance

A further component of the mechanism involves selectively reducing inhibitory signals, particularly those mediated by GABA, directed at the wake-promoting neurons. By selectively reducing the inhibitory signaling directed at arousal centers, Modasomil contributes to a net increase in the activity of excitatory neurotransmitters like dopamine and glutamate. This concerted physiological effect results in a stable activation of CNS arousal pathways.

Modasomil is a medication administered exclusively via the oral route as a solid tablet. The standard daily dosage for adults addressing excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD) is typically 200 mg.

The medicine is generally taken once daily. The timing of administration is condition-dependent: for narcolepsy and OSA, the dose should be taken in the morning. Conversely, patients treating SWD should take the dose approximately one hour before the start of their scheduled work shift. The tablets may be ingested with or without food. While a single morning dose is common, the total daily amount may be divided into two doses taken in the morning and at noon.

Dose modifications are required for specific populations. The daily amount should be reduced by one-half (e.g., to 100 mg) for patients who have severe hepatic impairment. For older adults (65 years and over), starting therapy at a lower daily dose should be considered due to potential changes in drug clearance. Modasomil is not approved for use in individuals under the age of 18.

A key procedural constraint states that for OSA, this medicine must be used only as an adjunct to primary treatment. Furthermore, for treatment extending beyond an initial short-term phase, the necessity of continuing the therapy must be periodically re-evaluated by the supervising physician.

Research evidence / Overview of Studies for Modasomil

Evidence for Use in Narcolepsy

The research exploring Modasomil for narcolepsy primarily involved short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing the compound to an inactive placebo to observe patterns. Researchers focused on monitoring objective measures of wakefulness, such as the Maintenance of Wakefulness Test (MWT), and patient-reported outcomes describing perceived discomfort from sleepiness.

While evidence exists from short-term trials, findings describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level. Long-term effects are not fully established; follow-up durations were limited in the core efficacy trials, which typically lasted less than three months. Furthermore, few data are available on other aspects of the condition, such as whether research has explored changes in cataplexy episodes.

Evidence for Use in Obstructive Sleep Apnea (OSA)

Research explored the study of Modasomil as an adjunct to primary treatment in individuals with Obstructive Sleep Apnea (OSA) who still experience excessive sleepiness. The studies conducted during periods of increased symptom activity focused on adults who were already using standard OSA therapies, such as CPAP.

Studies reported how symptoms evolved in the observed populations, with findings describing patterns observed in the studies related to measures of wakefulness. The research examined temporary physiological imbalance related to sleepiness, and studies did not evaluate whether the individual's underlying breathing condition is affected. The study findings reflect the specific design where all observed populations were receiving their primary OSA therapy.

Evidence for Use in Shift Work Disorder (SWD)

For individuals with excessive sleepiness associated with night or rotating shifts, Modasomil was evaluated in short-term RCTs. Studies monitored outcomes describing episodic or acute changes in alertness during the night work shift and during the subsequent vulnerable commute home. The majority of the available research explores short-term symptom changes, with follow-up durations being limited to typically 12 weeks.

What is Still Uncertain About Modasomil

Research provides context but not individual predictions. Certainty remains low regarding long-term effects across all patient groups, as follow-up durations were limited in the initial definitive trials. Data are still emerging, and evidence quality varies across studies regarding the functional benefits that extend far beyond objective wakefulness metrics. The overall research describes group patterns, not personal outcomes, and research provides context but not individual predictions.

Common questions about Modasomil (FAQ)

---

Q: Is Modasomil considered a traditional stimulant medication?

A: Modasomil is officially classified as a wakefulness-promoting agent or eugeroic, which is distinct from traditional Central Nervous System (CNS) stimulants. While it does promote wakefulness, regulatory sources indicate that its pharmacological profile is not identical to classic stimulant medications like amphetamines.

---

Q: How is Modasomil described as promoting wakefulness?

A: According to official product information, the drug works by binding to a location on the dopamine reuptake site. This action causes an increase in the concentration of dopamine outside of brain cells, which is associated with increased wakefulness and alertness.

---

Q: How quickly does Modasomil typically start to work after a dose?

A: Pharmacokinetic studies indicate that Modasomil is rapidly absorbed after being taken by mouth. The peak concentration of the drug in the bloodstream typically occurs at two to four hours after a dose is administered.

---

Q: How long does the wakefulness-promoting effect of Modasomil usually last?

A: Official information describes the drug's elimination half-life, which is the time it takes for half of the drug to be removed from the body, as approximately 15 hours. This half-life indicates a long duration of effect.

---

Q: What is the difference between Modasomil and Armodafinil (Nuvigil)?

A: Modasomil's active ingredient is Modafinil. Official labeling often mentions the related substance, Armodafinil, in its contraindications. This official relationship confirms they are distinct, yet related, substances.

---

Q: What is the general research evidence regarding the long-term effectiveness of Modasomil for approved uses?

A: Regulatory documents state that studies evaluating the long-term effectiveness of Modasomil for approved uses were typically limited in duration, often not extending beyond nine weeks. Regulatory guidelines require the necessity of continued therapy to be periodically re-evaluated by the supervising physician.

---

Q: Can I drink coffee or other caffeinated beverages while taking Modasomil?

A: Regulatory interaction data suggests caution regarding the combination of Modasomil with caffeine. The combination may be associated with an increase in blood pressure and heart rate. Monitoring of these parameters is recommended in the official safety profile for those with cardiovascular conditions.

---

Q: If Modasomil is taken with food, does it change the speed or onset of action?

A: Official prescribing information states that taking the drug with food does not change the total amount of medicine absorbed into the body. However, food intake may delay the time it takes to reach peak concentration in the blood by approximately one hour.

---

Q: Does Modasomil offer a permanent cure for sleep conditions like narcolepsy?

A: Official drug information from sources like the NIH indicates that Modasomil is used to manage excessive sleepiness but does not cure the underlying conditions. The drug is intended for management and functions while it is being taken, rather than providing a permanent solution.

---

Q: Can Modasomil be used to treat general tiredness or fatigue not caused by a diagnosed sleep disorder?

A: According to official indications, Modasomil is not approved for use in the treatment of general tiredness, nonspecific fatigue, or complaints of a lack of energy. Its use is limited to excessive sleepiness associated with specific diagnosed sleep disorders.

---

Q: Are there any known long-term side effects associated with Modasomil use?

A: The official safety profile includes post-marketing reports that indicate a potential for psychiatric symptoms and cardiovascular effects, such as increased heart rate and blood pressure, with long-term use. Close monitoring of these parameters is outlined in the safety documentation.

---

Q: Can Modasomil cause trouble with sleeping (insomnia), even though it promotes wakefulness?

A: Yes, official labeling lists insomnia, or trouble sleeping, as a common adverse reaction. It is a documented effect that may occur despite the drug’s primary role in promoting wakefulness.

---

Q: Does Modasomil have a potential for dependence or misuse according to regulatory bodies?

A: Modasomil is classified by the DEA as a Schedule IV controlled substance. This official classification indicates that the drug has a low potential for abuse and a low risk of physical or mental dependence.

---

Q: Are there known food or juice interactions with Modasomil, such as grapefruit?

A: Official drug information from sources like the NIH mentions the need for discussion with a healthcare provider regarding the consumption of grapefruit or grapefruit juice during treatment.

---

Q: Are there official recommendations regarding how long a person can continue to use Modasomil?

A: Official regulatory guidelines state that the necessity of continuing therapy is subject to periodic re-evaluation by the supervising physician, since long-term effectiveness has not been fully established.

---

Q: How does the potential for abuse of Modasomil compare to traditional Schedule II stimulants?

A: Modasomil is classified as a Schedule IV controlled substance. This classification is lower than that of Schedule II stimulants and reflects a lower potential for misuse and abuse compared to drugs in Schedule II.

---

Q: Is there scientific research supporting the use of Modasomil for non-sleep-related cognitive enhancement?

A: The drug is not approved or indicated for use in healthy individuals to address complaints of a lack of energy or fatigue. Official research and regulatory approval are restricted to the approved uses for diagnosed sleep disorders.

Storage and Disposal of Modasomil

Modasomil (Modafinil) tablets must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F), with permitted excursions up to 30°C. The medication must be kept in a closed container and protected from heat, moisture, and direct light; it must not be frozen.

Due to its classification as a controlled substance (C-IV), it is a mandatory regulatory requirement to keep Modasomil in a safe place and out of the reach of children to prevent unauthorized access.

For disposal, the best method is utilizing a drug take-back program. If this is not available, the tablets should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before being discarded in the household trash. The medication must not be flushed down a toilet or poured down a sink, and all disposal must comply with local regulatory requirements.